UEG Week Recordings UEG Week Posters Online courses Guidelines Mistakes in... Podcasts Webinars
new
Gut Guide online
Visit ueg.eu Create myUEG account Log In
Visit ueg.eu Create myUEG account Log In

Filters:

UEG Online Course
accredited
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

IBD epidemiology & aetiology

Bel Klaartje Kok, Charles Murray

Summary

AI Generated

This online course covers the epidemiology and aetiology of inflammatory bowel disease, including Crohn's disease and ulcerative colitis, with focus on genetics, the microbiome, and environmental factors.

  • The course explains worldwide incidence and prevalence of Crohn's disease and ulcerative colitis, the two main types of inflammatory bowel disease.
  • Environmental factors, the microbiome, and genetics are thought to contribute to the immune response that culminates in inflammation experienced by patients with IBD.
  • Learning objectives include familiarity with IBD epidemiology, genetic contributions, microbiome role, and environmental factor impacts.
  • The course is suitable for gastroenterologists in training, physicians and surgeons in other disciplines with IBD interest, nurses, biotechnicians, and advanced-years medical students interested in gastroenterology.
Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Overview

Crohn’s disease and ulcerative colitis — the two main types of inflammatory bowel disease (IBD) — are chronic, relapsing disorders that have a significant impact at both the individual and societal level. 

This online course explains current knowledge on the epidemiology and aetiology of IBD. Authors Klaartje Bel Kok and Charles Murray highlight what is known about the worldwide incidence and prevalence of Crohn’s disease and ulcerative colitis, and how environmental factors, the microbiome and genetics are thought to contribute to the immune response that culminates in the inflammation experienced by patients with IBD. 
 

Learning objectives

To become familiar with:

  • The epidemiology of inflammatory bowel disease (IBD)
  • The contribution of genetics to IBD
  • The role of the microbiome in IBD
  • The impact of environmental factors on IBD

Target audience

This course is suitable for gastroenterologists in training, but it is also appropriate for physicians and surgeons in other disciplines who have an interest in IBD, as well as nurses, biotechnicians and advanced-years’ medical students who have an interest in gastroenterology. 

Reviewed & updated July 2022

Event

IBD epidemiology & aetiology

Accreditation status

accredited

Duration

50 minutes

Published

2020

More Like This:

Acute pancreatitis

Acute pancreatitis

Markus M. Lerch Markus M. Lerch, Ali Alexander Aghdassi

DIFFERENCES IN CLINICAL HISTORY AND PRESENTATION IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING INPATIENT VERSUS OUTPATIENT LIVER TRANSPLANT EVALUATION

DIFFERENCES IN CLINICAL HISTORY AND PRESENTATION IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING INPATIENT VERSUS OUTPATIENT LIVER TRANSPLANT EVALUATION

Deepika Devuni Deepika Devuni, Katherine Cooper

ASSESSMENT OF INTESTINAL ULTRASOUND IN THE DIAGNOSIS OF POST-OPERATIVE RECURRENCE IN CROHN'S DISEASE

ASSESSMENT OF INTESTINAL ULTRASOUND IN THE DIAGNOSIS OF POST-OPERATIVE RECURRENCE IN CROHN'S DISEASE

María Dolores Martín-Arranz María Dolores Martín-Arranz, Joaquin Poza Cordón, Laura Garcia Ramirez, Irene González Díaz, Clara Amiama Roig, Kathy Silva, Eduardo Martín-Arranz, Maria Sanchez-Azofra, Jose Luis Rueda García, Cristina Suárez Ferrer, Carmen Amor Costa

REAL-WORLD EVIDENCE DATA WAREHOUSE FOR POOLED ANALYSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES IN GERMANY: THE “UMBRELLA-IBD REGISTRY” OF THE COMPETENCE NETWORK IBD

REAL-WORLD EVIDENCE DATA WAREHOUSE FOR POOLED ANALYSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES IN GERMANY: THE “UMBRELLA-IBD REGISTRY” OF THE COMPETENCE NETWORK IBD

Sandra Plachta-Danielzik Sandra Plachta-Danielzik, Stefan Schreiber, Arne Bokemeyer, Florian Tran, Elena Gilman, Thomas Wenske, Bernd Bokemeyer

SKELETAL MUSCLE DUPD1 LINKS COLITIS WITH OBESITY-ASSOCIATED METABOLIC DISEASES

SKELETAL MUSCLE DUPD1 LINKS COLITIS WITH OBESITY-ASSOCIATED METABOLIC DISEASES

Alberto Martin Alberto Martin, Saurav Roy Choudhury

ANTI-INFLAMMATORY EFFECTS OF HERICIUM ERINACEUS, BERBERINE, QUERCETIN, BIOTIN, AND NIACIN (HBQ-COMPLEX®) IN CROHN’S DISEASE AND ULCERATIVE COLITIS: AN EX VIVO TISSUE MODEL STUDY

ANTI-INFLAMMATORY EFFECTS OF HERICIUM ERINACEUS, BERBERINE, QUERCETIN, BIOTIN, AND NIACIN (HBQ-COMPLEX®) IN CROHN’S DISEASE AND ULCERATIVE COLITIS: AN EX VIVO TISSUE MODEL STUDY

Giusi Arboretto Giusi Arboretto, Alessandro Federico, Marco Romano, Fortunato Ciardiello, Concetta Tuccillo, Giovanni Brandimarte, Annachiara Coppola, Giovanna Palladino, Raffaele Pellegrino, Antonietta Gerarda Gravina

UEG Online Course
accredited
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Acute pancreatitis

Ali Alexander Aghdassi, Markus M. Lerch

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Overview

Acute pancreatitis is the most frequent pancreatic disease and the most common reason for emergency room admission for all nonmalignant gastrointestinal diseases. This rapid-onset and painful inflammation of the pancreas is troublesome to manage because it has a diverse and often unpredictable clinical course. Although the inflammation usually subsides, complications can develop, and some patients will progress to chronic pancreatitis.
Learning objectives

  • The aetiology of acute pancreatitis
  • The different classification systems for acute pancreatitis
  • The diagnosis of acute pancreatitis
  • The therapeutic regimes for acute pancreatitis
    Target audience

This course is suitable for gastroenterologists in training, but it is also appropriate for physicians and surgeons in other disciplines, as well as nurses, biotechnicians and advanced-years’ medical students who have an interest in gastroenterology.

Reviewed & updated February 2023

Event

Acute pancreatitis

Topics

Pancreas

Accreditation status

accredited

Duration

1 hour

Published

2020

More Like This:

Acute pancreatitis

Acute pancreatitis

Markus M. Lerch Markus M. Lerch, Ali Alexander Aghdassi

DIFFERENCES IN CLINICAL HISTORY AND PRESENTATION IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING INPATIENT VERSUS OUTPATIENT LIVER TRANSPLANT EVALUATION

DIFFERENCES IN CLINICAL HISTORY AND PRESENTATION IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING INPATIENT VERSUS OUTPATIENT LIVER TRANSPLANT EVALUATION

Deepika Devuni Deepika Devuni, Katherine Cooper

ASSESSMENT OF INTESTINAL ULTRASOUND IN THE DIAGNOSIS OF POST-OPERATIVE RECURRENCE IN CROHN'S DISEASE

ASSESSMENT OF INTESTINAL ULTRASOUND IN THE DIAGNOSIS OF POST-OPERATIVE RECURRENCE IN CROHN'S DISEASE

María Dolores Martín-Arranz María Dolores Martín-Arranz, Joaquin Poza Cordón, Laura Garcia Ramirez, Irene González Díaz, Clara Amiama Roig, Kathy Silva, Eduardo Martín-Arranz, Maria Sanchez-Azofra, Jose Luis Rueda García, Cristina Suárez Ferrer, Carmen Amor Costa

REAL-WORLD EVIDENCE DATA WAREHOUSE FOR POOLED ANALYSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES IN GERMANY: THE “UMBRELLA-IBD REGISTRY” OF THE COMPETENCE NETWORK IBD

REAL-WORLD EVIDENCE DATA WAREHOUSE FOR POOLED ANALYSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES IN GERMANY: THE “UMBRELLA-IBD REGISTRY” OF THE COMPETENCE NETWORK IBD

Sandra Plachta-Danielzik Sandra Plachta-Danielzik, Stefan Schreiber, Arne Bokemeyer, Florian Tran, Elena Gilman, Thomas Wenske, Bernd Bokemeyer

SKELETAL MUSCLE DUPD1 LINKS COLITIS WITH OBESITY-ASSOCIATED METABOLIC DISEASES

SKELETAL MUSCLE DUPD1 LINKS COLITIS WITH OBESITY-ASSOCIATED METABOLIC DISEASES

Alberto Martin Alberto Martin, Saurav Roy Choudhury

ANTI-INFLAMMATORY EFFECTS OF HERICIUM ERINACEUS, BERBERINE, QUERCETIN, BIOTIN, AND NIACIN (HBQ-COMPLEX®) IN CROHN’S DISEASE AND ULCERATIVE COLITIS: AN EX VIVO TISSUE MODEL STUDY

ANTI-INFLAMMATORY EFFECTS OF HERICIUM ERINACEUS, BERBERINE, QUERCETIN, BIOTIN, AND NIACIN (HBQ-COMPLEX®) IN CROHN’S DISEASE AND ULCERATIVE COLITIS: AN EX VIVO TISSUE MODEL STUDY

Giusi Arboretto Giusi Arboretto, Alessandro Federico, Marco Romano, Fortunato Ciardiello, Concetta Tuccillo, Giovanni Brandimarte, Annachiara Coppola, Giovanna Palladino, Raffaele Pellegrino, Antonietta Gerarda Gravina

UEG Poster
Standard Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

DIFFERENCES IN CLINICAL HISTORY AND PRESENTATION IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING INPATIENT VERSUS OUTPATIENT LIVER TRANSPLANT EVALUATION

Katherine Cooper 1, Deepika Devuni 1

Affiliations

1 UMass Chan Medical School, Worcester, United States

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Liver transplant is the only definitive treatment for chronic liver disease (CLD). Referral to a hepatologist for consideration for liver transplant should be made when a patient with CLD experiences a hepatic decompensation or has a MELD score ≥ 15. Failure to refer in a timely manner can result needing a liver transplant evaluation (LTE) in the inpatient setting while a patient is experiencing acute decompensation.

Aims & Methods

We aimed to compare the clinical presentation of patients undergoing LTE in the inpatient setting versus the outpatient setting to identify potential risk factors for requiring urgent evaluation. A list of all LTEs performed at our institution between 10/2017-8/2021 was obtained. Medical records were preliminarily reviewed for evaluation setting (Inpatient vs. Outpatients); evaluations for re-transplantation and acute liver failure were excluded. After all Inpatients (n=159) were identified, Outpatients (n=159) were selected at random to create a sample matched for age, gender, race, and ethnicity (n=318). Data were collected using our institutions electronic medical record and outside health records as obtained during LTE process. “Prior decompensations” refers to the number of the following clinical decompensations experienced prior to the time of LTE: ascites, hepatic encephalopathy (HE), variceal/acute UGIB, SBP and HRS. Categorical variables and continuous were compared between using Fisher’s Exact test, and student’s T test, respectively.

Results

Alcohol was the most common CLD etiology (42.1% Inpatient, 48.4% Outpatient). Inpatients tended to live further from our center than Outpatients (p=0.079). Inpatients had significantly higher MELD-Na scores (27.1 ± 8 vs. 13.3 ± 6; p<0.0001). Malnutrition was more common in 5.6 times more common in inpatients than outpatients (OR 5.6, 95% CI 2.9-10.8, p<0.001).. A similar proportion of patients had 1 hospitalization. But inpatients were 3 times as likely to have had ≥ 1 liver-related hospital admission prior to LTE (p<0.0001). Inpatients had significantly more prior decompensations than Outpatients prior to inpatient LTE (3.2 ± 1.4 vs. 1.8 ± 1.1, p<0.001), with the greatest differences in SBP and HRS.


VariableOutpatientInpatientp
Nutritional status (%)Malnutrition8.233.5<0.0001
Previous hospital admissions (%)0 admissions23.911.4<0.0001
1 admissions36.522.8
>1 admissions39.665.8
History of Decompensation (%)Ascites71.191.8<0.0001
HE50.371.10.0002
UGIB23.332.10.1029
SBP3.822.0<0.0001
HRS3.832.7<0.0001

Conclusion

Multiple liver-related hospitalizations and malnutrition may be considered a risk factor for ultimately needing inpatient LTE and should be taken seriously by health care providers caring for patients with CLD. Episodes of SBP and HRS should prompt providers to consider immediate or urgent LTE referral regardless of other factors.

References

Multiple liver-related hospitalizations may be considered a risk factor for ultimately needing inpatient LTE and should be taken seriously by health care providers caring for patients with CLD. Episodes of SBP and HRS should prompt providers to consider immediate or urgent LTE referral regardless of other factors.

Disclosure

D Devuni has received grant funding from Sequana Medical and receives grant support from the NIAAA (AA017986-11), both for research unrelated to this work.

Conference

UEG Week Copenhagen 2023

Topics

Hepatobiliary

Submission format

Abstract

Session

PP 07 Liver & biliary (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

More Like This:

Acute pancreatitis

Acute pancreatitis

Markus M. Lerch Markus M. Lerch, Ali Alexander Aghdassi

DIFFERENCES IN CLINICAL HISTORY AND PRESENTATION IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING INPATIENT VERSUS OUTPATIENT LIVER TRANSPLANT EVALUATION

DIFFERENCES IN CLINICAL HISTORY AND PRESENTATION IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING INPATIENT VERSUS OUTPATIENT LIVER TRANSPLANT EVALUATION

Deepika Devuni Deepika Devuni, Katherine Cooper

ASSESSMENT OF INTESTINAL ULTRASOUND IN THE DIAGNOSIS OF POST-OPERATIVE RECURRENCE IN CROHN'S DISEASE

ASSESSMENT OF INTESTINAL ULTRASOUND IN THE DIAGNOSIS OF POST-OPERATIVE RECURRENCE IN CROHN'S DISEASE

María Dolores Martín-Arranz María Dolores Martín-Arranz, Joaquin Poza Cordón, Laura Garcia Ramirez, Irene González Díaz, Clara Amiama Roig, Kathy Silva, Eduardo Martín-Arranz, Maria Sanchez-Azofra, Jose Luis Rueda García, Cristina Suárez Ferrer, Carmen Amor Costa

REAL-WORLD EVIDENCE DATA WAREHOUSE FOR POOLED ANALYSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES IN GERMANY: THE “UMBRELLA-IBD REGISTRY” OF THE COMPETENCE NETWORK IBD

REAL-WORLD EVIDENCE DATA WAREHOUSE FOR POOLED ANALYSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES IN GERMANY: THE “UMBRELLA-IBD REGISTRY” OF THE COMPETENCE NETWORK IBD

Sandra Plachta-Danielzik Sandra Plachta-Danielzik, Stefan Schreiber, Arne Bokemeyer, Florian Tran, Elena Gilman, Thomas Wenske, Bernd Bokemeyer

SKELETAL MUSCLE DUPD1 LINKS COLITIS WITH OBESITY-ASSOCIATED METABOLIC DISEASES

SKELETAL MUSCLE DUPD1 LINKS COLITIS WITH OBESITY-ASSOCIATED METABOLIC DISEASES

Alberto Martin Alberto Martin, Saurav Roy Choudhury

ANTI-INFLAMMATORY EFFECTS OF HERICIUM ERINACEUS, BERBERINE, QUERCETIN, BIOTIN, AND NIACIN (HBQ-COMPLEX®) IN CROHN’S DISEASE AND ULCERATIVE COLITIS: AN EX VIVO TISSUE MODEL STUDY

ANTI-INFLAMMATORY EFFECTS OF HERICIUM ERINACEUS, BERBERINE, QUERCETIN, BIOTIN, AND NIACIN (HBQ-COMPLEX®) IN CROHN’S DISEASE AND ULCERATIVE COLITIS: AN EX VIVO TISSUE MODEL STUDY

Giusi Arboretto Giusi Arboretto, Alessandro Federico, Marco Romano, Fortunato Ciardiello, Concetta Tuccillo, Giovanni Brandimarte, Annachiara Coppola, Giovanna Palladino, Raffaele Pellegrino, Antonietta Gerarda Gravina

UEG Poster
Standard Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

ASSESSMENT OF INTESTINAL ULTRASOUND IN THE DIAGNOSIS OF POST-OPERATIVE RECURRENCE IN CROHN'S DISEASE

Carmen Amor Costa 1, Cristina Suárez Ferrer 2, Joaquin Poza Cordón 3, Jose Luis Rueda García 3, Maria Sanchez-Azofra 3, Eduardo Martín-Arranz 3, Kathy Silva 4, Clara Amiama Roig 1, Irene González Díaz 1, Laura Garcia Ramirez 4, María Dolores Martín-Arranz 5

Affiliations

1 Hospital La Paz, Madrid, Spain

2 Hospital La Paz, Madrid, Spain|||Hospital La Paz Institute for Health Research (IdiPAZ)., Madrid, Spain

3 Hospital La Paz Institute for Health Research (IdiPAZ)., Madrid, Spain|||Hospital La Paz, Madrid, Spain

4 Hospital La Paz Institute for Health Research (IdiPAZ)., Madrid, Spain

5 Hospital La Paz, Madrid, Spain|||Hospital La Paz Institute for Health Research (IdiPAZ)., Madrid, Spain|||School of Medicine. Universidad Autónoma de Madrid, Madrid, Spain

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Ileocolonoscopy and Rutgeerts endoscopic score (RS) remains the gold standard to evaluate post-operative recurrence (POR) in Crohn's disease (CD). Intestinal ultrasound (IUS) is proposed as a non-invasive alternative for the diagnosis of POR, with a sensitivity of 89%, specificity of 86% and area under curve (AUC) of 0.93 (1). Bowel wall thickness (BWT) alone has a high accuracy in the diagnosis of POR and it is proposed that the association of other parameters such as hyperemia, loss of bowel wall stratification, involvement of mesenteric fat (i-fat) or ultrasound scores, increases sensitivity and specificity in the diagnosis of POR (2).

Aims & Methods

The aim of this study is to assess whether IUS parameters and ultrasound scores correlate with endoscopy in the diagnosis of POR. A unicentric retrospective study was performed. There were included patients with CD with both an ileocolonoscopy and intestinal ultrasound performed for the detection of POR, the time between tests was less than 6 months or there was no therapeutic change between tests.
Endoscopic POR was evaluated with Rutgeers score (RS), RS i0 and i1 was considered no POR and RS ≥i2a was POR. The IUS parameters were: BWT, Limberg Score, bowel wall stratification, inflammation of mesenteric fat, Simple US Score, SUS-CD and IBUS-SAS score.

Results

129 patients were included, baseline characteristics are in Table 1. In 108 patients (83.7%) the time between test was <6 months and in 21 (16.3%) >6 months without therapeutic changes. 38 (29.7%) were classified as endoscopic POR (RS i0 – i1) and 90 (69.8%) as POR: 28 (21.2%) i2a, 17 (13.3%) i2b and 45 (35.1%) severe (RS i3 – i4). With IUS, 42 patients (32.6%) were classified as no POR and 87 (67.4%) as POR. The mean BWT by IUS in patients without endoscopic POR was 2.6 mm (SD +/- 1.2) versus 4.8 (SD +/- 1.6) in patients with RS ≥i2a (p 0.001). BWT ≥3 had a sensitivity of 86.6%, specificity 78.9% and AUC of 0.83 in the diagnosis of POR. Hyperemia (Limberg ≥1) was present in 75 patients (84.3%) with RS ≥i2a versus in 8 patients (21.1%) without endoscopic POR (p 0.001). 21 patients (23.9%) of patients with RS ≥i2a presented loss of bowel wall stratification versus 0 (0%) with i0-i1 (p 0.001). I-fat was present in 16 patients (12.4%), all of them RS ≥i2a (p 0.02).
The mean results of IUS scores were: Simple Us score 5.6 (SD +/- 2.9), SUS-CD 2.1 (SD +/- 1.8) and IBUS-SAS 31.6 (SD +/- 23.3). In patients without endoscopic POR the mean result of Simple US Score was 3.0 (SD +/- 2.0) versus 6.7 (SD +/- 2.4) in RS ≥i2a (p>0.05). The mean result of SUS-CD without POR was 0.5 (SD +/ 1.0) versus 2.8 (SD +/- 1.5) in POR (p>0.05). In IBUS-SAS the mean result in RS i0-i1 was 13.4 (SD +/- 10.8) versus 39.2 (SD +/- 22.9) in RS ≥i2a (p>0.05). Simple US Score showed an AUC of 0.85 in the diagnosis of POR (95% CI 0.78 – 0.92), SUS-CD of 0.87 (95% CI 0.81 – 0.93) and IBUS-SAS of 0.85 (95% CI 0.77 – 0.92).

Variablen 129
Men (%)65 (50.4)
Active smoking (%)32 (25.4)
Montreal classification (%)
- L1
- L2
- L3
- L4
- B1
- B2
- B3
- p
59 (45.7)
2 (1.5)
60 (46.5)
8 (6.2)
19 (14.7)
49 (38.0)
61 (47.3)
8 (6.2)
Preventive treatment (%)
- None
- Inmunomodulator
- Biological therapy
- Inmunomodulator + biological
35 (27.1)
39 (30.2)
33 (25.6)
21 (16.3)
C-reactive protein (mg/L) (mean, SD)16.3 (127.7)
Fecal calprotectin (µg/g) (mean, SD)192.1 (391.6)
Bowel wall thickness (mm) (mean, SD)4.1 (1.8)
Limberg score (0-3) (mean, SD)
1.5 (1.2)
Loss of bowel wall stratification (%)21 (16.5)

Conclusion

In our experience, IUS parameters such as BWT, Limberg score, loss of wall stratification, i-fat and IUS scores (IBUS-SAS, SUS-CD and Simple US Score), have a high accuracy in the diagnosis of POR.

References

1. Barchi, Alberto et al. “Recent advances in the use of ultrasound in Crohn's disease.” Expert review of medical devices vol. 20,12 (2023): 1119-1129. doi:10.1080/17434440.2023.2283166
2. Yung, Diana E et al. “Capsule Endoscopy, Magnetic Resonance Enterography, and Small Bowel Ultrasound for Evaluation of Postoperative Recurrence in Crohn's Disease: Systematic Review and Meta-Analysis.” Inflammatory bowel diseases vol. 24,1 (2017): 93-100. doi:10.1093/ibd/izx027

Conference

UEG Week Vienna 2024

Topics

IBD

Submission format

Abstract

Session

IBD (Posters)

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

More Like This:

Acute pancreatitis

Acute pancreatitis

Markus M. Lerch Markus M. Lerch, Ali Alexander Aghdassi

DIFFERENCES IN CLINICAL HISTORY AND PRESENTATION IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING INPATIENT VERSUS OUTPATIENT LIVER TRANSPLANT EVALUATION

DIFFERENCES IN CLINICAL HISTORY AND PRESENTATION IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING INPATIENT VERSUS OUTPATIENT LIVER TRANSPLANT EVALUATION

Deepika Devuni Deepika Devuni, Katherine Cooper

ASSESSMENT OF INTESTINAL ULTRASOUND IN THE DIAGNOSIS OF POST-OPERATIVE RECURRENCE IN CROHN'S DISEASE

ASSESSMENT OF INTESTINAL ULTRASOUND IN THE DIAGNOSIS OF POST-OPERATIVE RECURRENCE IN CROHN'S DISEASE

María Dolores Martín-Arranz María Dolores Martín-Arranz, Joaquin Poza Cordón, Laura Garcia Ramirez, Irene González Díaz, Clara Amiama Roig, Kathy Silva, Eduardo Martín-Arranz, Maria Sanchez-Azofra, Jose Luis Rueda García, Cristina Suárez Ferrer, Carmen Amor Costa

REAL-WORLD EVIDENCE DATA WAREHOUSE FOR POOLED ANALYSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES IN GERMANY: THE “UMBRELLA-IBD REGISTRY” OF THE COMPETENCE NETWORK IBD

REAL-WORLD EVIDENCE DATA WAREHOUSE FOR POOLED ANALYSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES IN GERMANY: THE “UMBRELLA-IBD REGISTRY” OF THE COMPETENCE NETWORK IBD

Sandra Plachta-Danielzik Sandra Plachta-Danielzik, Stefan Schreiber, Arne Bokemeyer, Florian Tran, Elena Gilman, Thomas Wenske, Bernd Bokemeyer

SKELETAL MUSCLE DUPD1 LINKS COLITIS WITH OBESITY-ASSOCIATED METABOLIC DISEASES

SKELETAL MUSCLE DUPD1 LINKS COLITIS WITH OBESITY-ASSOCIATED METABOLIC DISEASES

Alberto Martin Alberto Martin, Saurav Roy Choudhury

ANTI-INFLAMMATORY EFFECTS OF HERICIUM ERINACEUS, BERBERINE, QUERCETIN, BIOTIN, AND NIACIN (HBQ-COMPLEX®) IN CROHN’S DISEASE AND ULCERATIVE COLITIS: AN EX VIVO TISSUE MODEL STUDY

ANTI-INFLAMMATORY EFFECTS OF HERICIUM ERINACEUS, BERBERINE, QUERCETIN, BIOTIN, AND NIACIN (HBQ-COMPLEX®) IN CROHN’S DISEASE AND ULCERATIVE COLITIS: AN EX VIVO TISSUE MODEL STUDY

Giusi Arboretto Giusi Arboretto, Alessandro Federico, Marco Romano, Fortunato Ciardiello, Concetta Tuccillo, Giovanni Brandimarte, Annachiara Coppola, Giovanna Palladino, Raffaele Pellegrino, Antonietta Gerarda Gravina

UEG Poster
Standard Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

REAL-WORLD EVIDENCE DATA WAREHOUSE FOR POOLED ANALYSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES IN GERMANY: THE “UMBRELLA-IBD REGISTRY” OF THE COMPETENCE NETWORK IBD

Bernd Bokemeyer 1, Sandra Plachta-Danielzik 2, Thomas Wenske 2, Elena Gilman 2, Florian Tran 3, Arne Bokemeyer 4, Stefan Schreiber 5

Affiliations

1 Interdisciplinary Crohn Colitis Centre Minden, Minden, Germany|||University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany|||Competence Network IBD, Kiel, Germany

2 Competence Network IBD, Kiel, Germany

3 University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany

4 University Hospital Essen, Essen, Germany

5 University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany|||Competence Network IBD, Kiel, Germany

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Head-to-head (H2H) comparisons of biologics and small molecules in randomised clinical trials (RCTs) are considered the gold standard in inflammatory bowel disease (IBD). However, comparative real-world evidence (RWE) registry studies can provide important additional knowledge. Our aim is to perform a range of such H2H RWE studies, including subgroup analyses, to examine different treatments in patients with IBD. To do so, we draw upon data from a large data warehouse (UMBRELLA-IBD), which pools data from all eight prospective RWE registries in the Competence Network IBD. All patients were recruited to each registry in a similar manner.

Aims & Methods

Pooled analyses have a range of important methodological and logistical requirements, all of which are met in the eight prospective RWE registries that feed data into the UMBRELLA-IBD data warehouse: (1) The prospectively collected data are highly homogeneous, with each registry using similar inclusion and exclusion criteria, and the analyses of registry data using similar outcome parameters; (2) The quality of the data is high, and the data are comparable due to comprehensive remote and onsite monitoring; (3) The advanced statistical methods used to compensate for the absence of randomisation include propensity score adjustment with inverse probability of treatment weighting (IPTW) and are applied similarly in each analysis (Table 1). In concordance with a priori protocols, data and parameters from the eight Competence Network IBD registries were checked for consistency, merged and then migrated to a common server. Additionally, a data validation plan (DVP) was created to process all data, with individual items being adapted by appropriate recoding for the pooled evaluation.

Results


In the new UMBRELLA-IBD data warehouse of the Competence Network IBD, prospectively recorded data from a total of 6,689 IBD patients in eight registry studies in Germany are available for a planned pooled analysis (Table 1), albeit with some patients potentially having been recruited to more than one of these studies. As of 31 March 2023, 35% of the patients included in the data warehouse are biologic-naïve and started their first biologic/small molecule treatment at recruitment. Prospectively documented one-year records are available for 75% of patients, and supplementary biomaterials have been collected in 40% of patients. Recruitment and follow-up are ongoing in some registries.

Table 1: IBD patients in the prospective registries of the Competence Network IBD at a glance: Umbrella-IBD (as of 31 March 2023)
* Some patients may be recruited in more than one study

Prospective RWE registries in the Competence Network IBDPatients with IBDStudy durationBio-naïve
patients 		Pts. with short course of disease CD/UCBiomaterials in
(%) of patients		Month 12 visit
documented
BioCrohn1,5302008 - 2018393677 (< 3 years)CD85%1,216
BioColitis8832013 - 2021238447 (< 2 years)UC51%666
Run-CD9012017 - 2024301-CD30%802
VEDO-IBD1,2842017 - 2022824150 (< 2 years)CD/UC51%937
IBD-Inception Registry1402016 - 2019
140 (< 1 year)CD/UC-110
RUN-UC5072020 -2024238-UC-387
FilgoColitis1622022 - 202522-UC-28
TARGET1,2822019 - ongoing308-CD/UC-861
IBD patients included in total*6,6892008 - today2,3241414CD/UC
5,007

Conclusion

The large UMBRELLA-IBD RWE data warehouse from eight different prospective Competence Network IBD registries is a promising initiative for conducting further comparative studies that will provide important evidence in addition to that from existing RCTs in IBD patients.

Disclosure

BB has received consulting fees from: AbbVie, MSD, Shire, Ferring, Hospira, Takeda, Galapagos, Shield Therapeutics, Pfizer, Biogen, Janssen, Hexal, and Celgene, outside the submitted work. Financial support for lectures and teaching from: AbbVie, Ferring, MSD, Merckle, Falk, Galapagos, Shield Therapeutics, Pfizer, Celltrion, Takeda, and Janssen. Grant and financial support for research from AbbVie, Takeda, Jansen, Pfizer, Galapagos, and Ferring, outside the submitted work. SPD has no relevant financial or non-financial interests to disclose. TW has no relevant financial or non-financial interests to disclose. EG has no relevant financial or non-financial interests to disclose. FT receives scientific funding from Sanofi, received consulting fee's from LEK Consulting and speaker's fee from Lilly, Janssen, Falk, Abbvie, Celltrion, onkowissen.de, CED Service GmbH. AB received consulting and speaker's fee from Abbvie, Amgen, BMS, Falk, Ferring, Janssen, Pfizer, Sanofi and Takeda. SS has served as a consultant or advisory board member for AbbVie, Amgen, Arena, Bristol Myers Squibb, Biogen, Celltrion, Celgene, Ferring, Fresenius, Galapagos, Gilead, HIKMA, IMAB, Janssen, Lilly, MSD, Mylan, Pfizer, Protagonist, Provention Bio, Sandoz/Hexal, Takeda, Theravance and UCB.

Conference

UEG Week Copenhagen 2023

Topics

IBD

Submission format

Abstract

Session

PP 05 IBD (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

More Like This:

Acute pancreatitis

Acute pancreatitis

Markus M. Lerch Markus M. Lerch, Ali Alexander Aghdassi

DIFFERENCES IN CLINICAL HISTORY AND PRESENTATION IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING INPATIENT VERSUS OUTPATIENT LIVER TRANSPLANT EVALUATION

DIFFERENCES IN CLINICAL HISTORY AND PRESENTATION IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING INPATIENT VERSUS OUTPATIENT LIVER TRANSPLANT EVALUATION

Deepika Devuni Deepika Devuni, Katherine Cooper

ASSESSMENT OF INTESTINAL ULTRASOUND IN THE DIAGNOSIS OF POST-OPERATIVE RECURRENCE IN CROHN'S DISEASE

ASSESSMENT OF INTESTINAL ULTRASOUND IN THE DIAGNOSIS OF POST-OPERATIVE RECURRENCE IN CROHN'S DISEASE

María Dolores Martín-Arranz María Dolores Martín-Arranz, Joaquin Poza Cordón, Laura Garcia Ramirez, Irene González Díaz, Clara Amiama Roig, Kathy Silva, Eduardo Martín-Arranz, Maria Sanchez-Azofra, Jose Luis Rueda García, Cristina Suárez Ferrer, Carmen Amor Costa

REAL-WORLD EVIDENCE DATA WAREHOUSE FOR POOLED ANALYSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES IN GERMANY: THE “UMBRELLA-IBD REGISTRY” OF THE COMPETENCE NETWORK IBD

REAL-WORLD EVIDENCE DATA WAREHOUSE FOR POOLED ANALYSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES IN GERMANY: THE “UMBRELLA-IBD REGISTRY” OF THE COMPETENCE NETWORK IBD

Sandra Plachta-Danielzik Sandra Plachta-Danielzik, Stefan Schreiber, Arne Bokemeyer, Florian Tran, Elena Gilman, Thomas Wenske, Bernd Bokemeyer

SKELETAL MUSCLE DUPD1 LINKS COLITIS WITH OBESITY-ASSOCIATED METABOLIC DISEASES

SKELETAL MUSCLE DUPD1 LINKS COLITIS WITH OBESITY-ASSOCIATED METABOLIC DISEASES

Alberto Martin Alberto Martin, Saurav Roy Choudhury

ANTI-INFLAMMATORY EFFECTS OF HERICIUM ERINACEUS, BERBERINE, QUERCETIN, BIOTIN, AND NIACIN (HBQ-COMPLEX®) IN CROHN’S DISEASE AND ULCERATIVE COLITIS: AN EX VIVO TISSUE MODEL STUDY

ANTI-INFLAMMATORY EFFECTS OF HERICIUM ERINACEUS, BERBERINE, QUERCETIN, BIOTIN, AND NIACIN (HBQ-COMPLEX®) IN CROHN’S DISEASE AND ULCERATIVE COLITIS: AN EX VIVO TISSUE MODEL STUDY

Giusi Arboretto Giusi Arboretto, Alessandro Federico, Marco Romano, Fortunato Ciardiello, Concetta Tuccillo, Giovanni Brandimarte, Annachiara Coppola, Giovanna Palladino, Raffaele Pellegrino, Antonietta Gerarda Gravina

UEG Poster
Standard Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

SKELETAL MUSCLE DUPD1 LINKS COLITIS WITH OBESITY-ASSOCIATED METABOLIC DISEASES

Saurav Roy Choudhury 1, Alberto Martin 1

Affiliations

1 University of Toronto, Toronto, Canada

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Inflammatory bowel disease (IBD), comprising of Crohn’s disease and Ulcerative Colitis (UC), is a debilitating inflammatory disease of the gastrointestinal tract with no known cause. Although extensive work has linked numerous genetic loci to IBD, most of these associations remain poorly understood. In addition, some studies have associated IBD to metabolic diseases such as diabetes and non-alcoholic fatty liver disease (NAFLD), although the precise molecular and pathophysiological mechanisms underlying these associations are unknown.

Aims & Methods

The central objective of this study was to understand the molecular mechanisms underlying the associations between IBD and obesity related metabolic diseases. To address this research question, we used multiple mouse models of colitis (dextran sodium sulfate or DSS), DSS and Azoxymethane induced colitis associated colon cancer and Helicobacter hepaticus infection induced colitis in Il-10-/- mice) and high fat diet (HFD) and genetic models of obesity and obesity associated metabolic diseases. In addition, for mechanistic studies, we used chimeric mice generated through bone marrow transplantation as well as conditional knockout mouse models. Lastly, we employed CRISPR/Cas9 edited cells in vitro to understand the molecular mechanism.

Results

Employing multiple murine models of colitis, colitis-associated colon cancer (CAC) and obesity associated metabolic diseases, we have identified DUPD1, a phosphatase of unknown function, that links IBD with metabolic diseases. Specifically, Dupd1-/-mice are protected from dextran sodium sulfate (DSS) and Helicobacter hepaticus induced colitis, and DSS/azoxymethane (AOM) induced CAC. Dupd1-/- mice also exhibited protection against high fat diet (HFD) induced obesity and fatty liver disease and glucose intolerance. DUPD1 is highly expressed in the skeletal muscle. Indeed, using skeletal muscle specific conditional DUPD1 knockout mice (Dupd1fl/flMyf6Cre), we show that DUPD1 exerts its colitogenic effects from the skeletal muscle through modulation of autophagy, a pathway whose dysfunction is known to play a role in IBD. Importantly, a dual specificity phosphatase inhibitor (NSC-663284) inhibited DUPD1 enzyme activity and reduced DSS-induced colitis in wild type mice but not in Dupd1-/-mice.

Conclusion

Our study identifies Dupd1 as a central gene that links IBD and obesity-associated metabolic diseases and suggests that it is a new therapeutic target in IBD, and obesity associated metabolic diseases.

Disclosure

Nothing to declare.

Conference

UEG Week Copenhagen 2023

Topics

IBD

Submission format

Abstract

Session

PP 05 IBD (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

More Like This:

Acute pancreatitis

Acute pancreatitis

Markus M. Lerch Markus M. Lerch, Ali Alexander Aghdassi

DIFFERENCES IN CLINICAL HISTORY AND PRESENTATION IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING INPATIENT VERSUS OUTPATIENT LIVER TRANSPLANT EVALUATION

DIFFERENCES IN CLINICAL HISTORY AND PRESENTATION IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING INPATIENT VERSUS OUTPATIENT LIVER TRANSPLANT EVALUATION

Deepika Devuni Deepika Devuni, Katherine Cooper

ASSESSMENT OF INTESTINAL ULTRASOUND IN THE DIAGNOSIS OF POST-OPERATIVE RECURRENCE IN CROHN'S DISEASE

ASSESSMENT OF INTESTINAL ULTRASOUND IN THE DIAGNOSIS OF POST-OPERATIVE RECURRENCE IN CROHN'S DISEASE

María Dolores Martín-Arranz María Dolores Martín-Arranz, Joaquin Poza Cordón, Laura Garcia Ramirez, Irene González Díaz, Clara Amiama Roig, Kathy Silva, Eduardo Martín-Arranz, Maria Sanchez-Azofra, Jose Luis Rueda García, Cristina Suárez Ferrer, Carmen Amor Costa

REAL-WORLD EVIDENCE DATA WAREHOUSE FOR POOLED ANALYSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES IN GERMANY: THE “UMBRELLA-IBD REGISTRY” OF THE COMPETENCE NETWORK IBD

REAL-WORLD EVIDENCE DATA WAREHOUSE FOR POOLED ANALYSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES IN GERMANY: THE “UMBRELLA-IBD REGISTRY” OF THE COMPETENCE NETWORK IBD

Sandra Plachta-Danielzik Sandra Plachta-Danielzik, Stefan Schreiber, Arne Bokemeyer, Florian Tran, Elena Gilman, Thomas Wenske, Bernd Bokemeyer

SKELETAL MUSCLE DUPD1 LINKS COLITIS WITH OBESITY-ASSOCIATED METABOLIC DISEASES

SKELETAL MUSCLE DUPD1 LINKS COLITIS WITH OBESITY-ASSOCIATED METABOLIC DISEASES

Alberto Martin Alberto Martin, Saurav Roy Choudhury

ANTI-INFLAMMATORY EFFECTS OF HERICIUM ERINACEUS, BERBERINE, QUERCETIN, BIOTIN, AND NIACIN (HBQ-COMPLEX®) IN CROHN’S DISEASE AND ULCERATIVE COLITIS: AN EX VIVO TISSUE MODEL STUDY

ANTI-INFLAMMATORY EFFECTS OF HERICIUM ERINACEUS, BERBERINE, QUERCETIN, BIOTIN, AND NIACIN (HBQ-COMPLEX®) IN CROHN’S DISEASE AND ULCERATIVE COLITIS: AN EX VIVO TISSUE MODEL STUDY

Giusi Arboretto Giusi Arboretto, Alessandro Federico, Marco Romano, Fortunato Ciardiello, Concetta Tuccillo, Giovanni Brandimarte, Annachiara Coppola, Giovanna Palladino, Raffaele Pellegrino, Antonietta Gerarda Gravina

UEG Poster
Standard Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

ANTI-INFLAMMATORY EFFECTS OF HERICIUM ERINACEUS, BERBERINE, QUERCETIN, BIOTIN, AND NIACIN (HBQ-COMPLEX®) IN CROHN’S DISEASE AND ULCERATIVE COLITIS: AN EX VIVO TISSUE MODEL STUDY

Antonietta Gerarda Gravina 1, Raffaele Pellegrino 1, Giovanna Palladino 1, Annachiara Coppola 1, Giusi Arboretto 1, Giovanni Brandimarte 2, Concetta Tuccillo 1, Fortunato Ciardiello 1, Marco Romano 1, Alessandro Federico 1

Affiliations

1 University of Campania "Luigi Vanvitelli", Naples, Italy

2 Cristo Re Hospital, Rome, Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Hericium erinaceus (H. erinaceus), berberine and quercetin showed anti-inflammatory potential in mouse models of experimental colitis. H. erinaceus (class Agaricomycetes, phylum Basidiomycota) is a mushroom belonging to traditional Chinese medicine that has been demonstrated in experimental colitis to be able to control pathways induced by Nuclear Factor kappa-light-chain-enhancer of activated B cells in an anti-inflammatory direction by suppressing the production of Tumor Necrosis Factor (TNF) and increasing the expression of Interleukin-10 (IL-10).

Aims & Methods

This ex vivo study aimed to evaluate the anti-inflammatory potential of a nutraceutical compound of H. erinaceus, berberine, quercetin, biotin and niacin (HBQ-Complex®) in Inflammatory bowel diseases (IBD) tissues obtained from both Normal-Appearing Mucosa (NAM) and Inflamed Mucosa (IM) tracts of patients with Crohn's Disease (CD) and patients with Ulcerative Colitis (CD). NAM tracts were identified from colic segments with Simple Endoscopic Score for CD = 0 or Mayo Endoscopic subscore = 0 (for CD and UC, respectively). NAM and one IM samples were frozen at -70° and then evaluated at T0. Two other IM samples were grown in DMEM medium in a temperature-controlled incubator and exposed to HBQ-Complex® for 120 minutes (T1) and 180 minutes (T2). RT-PCR and Western blot evaluations were performed for TNF, IL-10 and cyclooxygenase 2 (COX-2) at T0, T1, and T2. The HBQ-Complex® consisted of 525 mg of H. erinaceus powder (5 % polysaccharides from sporophorum) and 225 mg of H. erinaceus as an extract (30 % polysaccharides from sporophorum), 75 mg of quercetin titled to 98 %, 225 μg of biotin, 27 mg of niacin and, finally, 75 mg of Berberis vulgaris titled to 97 %.

Results

20 IBD treatment-naïve patients (50% CD, 50% UC) were enrolled. None of them had other comorbidities or was taking drug therapies within six months of the start of the study. According to the Harvey-Bradshaw index and partial Mayo score, four patients had mild CD and six moderate CD. The same was for UC patients. At T0, both CD and UC samples showed TNF and COX-2 genic expressions higher in IM than NAM (p < 0.0001). In IM samples, Incubation with HBQ-Complex® resulted in a progressive decrease in gene and protein COX-2 and TNF expression at T1/T2 in CD (p=0.002) and UC (p=0.003) samples. However, IL-10 showed an opposite trend, with a progressive genic expression increase from T0 to T1 (p=0.054) and T1 to T2 (p=0.002). The same was for UC samples (p < 0.01). These variations in PCR expressions of mRNAs were also recalculated from the same protein variations at Western blot analysis.

Conclusion

HBQ-Complex® might possess nutraceutical therapeutic potential in IBD. This could be explored in translational studies evaluating whether HBQ-Complex® can impact IBD's already validated clinical, endoscopic, and histological parameters.

References

- Diling C, Chaoqun Z, Jian Y, Jian L, Jiyan S, Yizhen X, et al. Immunomodulatory Activities of a Fungal Protein Extracted from Hericium erinaceus through Regulating the Gut Microbiota. Front Immunol. 2017;8:666.
- Ren Y, Geng Y, Du Y, Li W, Lu ZM, Xu HY, et al. Polysaccharide of Hericium erinaceus attenuates colitis in C57BL/6 mice via regulation of oxidative stress, inflammation-related signaling pathways and modulating the composition of the gut microbiota. J Nutr Biochem. luglio 2018;57:67–76.
- Qin M, Geng Y, Lu Z, Xu H, Shi JS, Xu X, et al. Anti-Inflammatory Effects of Ethanol Extract of Lion’s Mane Medicinal Mushroom, Hericium erinaceus (Agaricomycetes), in Mice with Ulcerative Colitis. Int J Med Mushrooms. 2016;18(3):227–34.

Conference

UEG Week Copenhagen 2023

Topics

IBD

Submission format

Abstract

Session

PP 05 IBD (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

More Like This:

Acute pancreatitis

Acute pancreatitis

Markus M. Lerch Markus M. Lerch, Ali Alexander Aghdassi

DIFFERENCES IN CLINICAL HISTORY AND PRESENTATION IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING INPATIENT VERSUS OUTPATIENT LIVER TRANSPLANT EVALUATION

DIFFERENCES IN CLINICAL HISTORY AND PRESENTATION IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING INPATIENT VERSUS OUTPATIENT LIVER TRANSPLANT EVALUATION

Deepika Devuni Deepika Devuni, Katherine Cooper

ASSESSMENT OF INTESTINAL ULTRASOUND IN THE DIAGNOSIS OF POST-OPERATIVE RECURRENCE IN CROHN'S DISEASE

ASSESSMENT OF INTESTINAL ULTRASOUND IN THE DIAGNOSIS OF POST-OPERATIVE RECURRENCE IN CROHN'S DISEASE

María Dolores Martín-Arranz María Dolores Martín-Arranz, Joaquin Poza Cordón, Laura Garcia Ramirez, Irene González Díaz, Clara Amiama Roig, Kathy Silva, Eduardo Martín-Arranz, Maria Sanchez-Azofra, Jose Luis Rueda García, Cristina Suárez Ferrer, Carmen Amor Costa

REAL-WORLD EVIDENCE DATA WAREHOUSE FOR POOLED ANALYSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES IN GERMANY: THE “UMBRELLA-IBD REGISTRY” OF THE COMPETENCE NETWORK IBD

REAL-WORLD EVIDENCE DATA WAREHOUSE FOR POOLED ANALYSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES IN GERMANY: THE “UMBRELLA-IBD REGISTRY” OF THE COMPETENCE NETWORK IBD

Sandra Plachta-Danielzik Sandra Plachta-Danielzik, Stefan Schreiber, Arne Bokemeyer, Florian Tran, Elena Gilman, Thomas Wenske, Bernd Bokemeyer

SKELETAL MUSCLE DUPD1 LINKS COLITIS WITH OBESITY-ASSOCIATED METABOLIC DISEASES

SKELETAL MUSCLE DUPD1 LINKS COLITIS WITH OBESITY-ASSOCIATED METABOLIC DISEASES

Alberto Martin Alberto Martin, Saurav Roy Choudhury

ANTI-INFLAMMATORY EFFECTS OF HERICIUM ERINACEUS, BERBERINE, QUERCETIN, BIOTIN, AND NIACIN (HBQ-COMPLEX®) IN CROHN’S DISEASE AND ULCERATIVE COLITIS: AN EX VIVO TISSUE MODEL STUDY

ANTI-INFLAMMATORY EFFECTS OF HERICIUM ERINACEUS, BERBERINE, QUERCETIN, BIOTIN, AND NIACIN (HBQ-COMPLEX®) IN CROHN’S DISEASE AND ULCERATIVE COLITIS: AN EX VIVO TISSUE MODEL STUDY

Giusi Arboretto Giusi Arboretto, Alessandro Federico, Marco Romano, Fortunato Ciardiello, Concetta Tuccillo, Giovanni Brandimarte, Annachiara Coppola, Giovanna Palladino, Raffaele Pellegrino, Antonietta Gerarda Gravina

The global reference point for the digestive health community

Platform Publisher

United European Gastroenterology

Wickenburggasse 1 1080 Vienna, Austria

Contact us

support@ueg.eu

ueg.eu

T: +43 1 997 1639

Legal

Terms & Conditions

Imprint

Privacy Policy

Explore

My Bookmarks

My recommendations

My fields of interest

© 2026 United European Gastroenterology

Change fields of interest

These fields are selected based on the interests in your myUEG profile.
Click the item to unselect it. You can select multiple items.